Triazenes pp 185-193 | Cite as

Experimental Background and Early Clinical Studies with Imidazotetrazine Derivatives

  • E. S. Newlands
  • G. R. P. Blackledge
  • J. Slack
  • N. S. A. Stuart
  • M. F. G. Stevens

Abstract

A series of imidazotetrazine derivatives were synthesised by Stevens and colleagues in the late 70′s (1). The activity of one of these derivatives, mitozolamide (8-carbamoyl-3-(2-chloroethyl)imidazo[5-1-d]-1,2,3,5-tetrazin-4(3H)-one) was identified and the compound’s ability to cross link DNA confirmed (2, 3, 4).

Keywords

Anti Tumour Activity Small Cell Carcinoma Murine System P388 Leukaemia Charing Cross Hospital 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    M.F.G. Stevens. The medical chemistry of 1,2,3 triazines. Prog. Med. Chem. 13: 205–269 (1976).PubMedCrossRefGoogle Scholar
  2. 2.
    K. Vaughan and M.F.G. Stevens Monoalkyltriazines. Chem. Soc. Rev. 7: 377–397 (1978).CrossRefGoogle Scholar
  3. 3.
    M.F.G. Stevens, J.A. Hickman, R. Stone et al. Antitumour imidazotetrazines 1. Synthesis and chemistry of 8-carbamoyl 3-(2-chloroethyl)imidazo[5,1,D]-1,2,3,5-tetrazin-4(3H)-one, a novel broad spectrum antitumour agent. J. Med. Chem. 27: 196–201, 1984.PubMedCrossRefGoogle Scholar
  4. 4.
    N.W. Gibson, L.C. Erickson & J.A. Hickman. Effects of the antitumour agent 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one on the DNA of mouse L1210 cells. Cancer Res. 44: 1767–1771 (1984).PubMedGoogle Scholar
  5. 5.
    N.W. Gibson, J. A. Hickman & L.C. Erickson. DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl) imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one. Cancer Res. 44: 1772–1775 (1984).PubMedGoogle Scholar
  6. 6.
    M.F.G. Stevens, J.A. Hickman, S.P. Langdon, D. Chubb, L. Vickers, R. Stone, G. Baig, C. Goddard, N.W. Gibson, J.A. Slack, C. Newton, E. Lunt, C. Fizames and & F. Lavelle. Antitumour activity and pharmacokinetics in mice of 8-carbamoyl-3-methlyimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 47: 5846–5852 (1987).PubMedGoogle Scholar
  7. 7.
    C.M. Horgan & M.J. Tisdale. Antitumour imidazotetrazines — IV. An investigation into the mechanism of antitumour activity of a novel and potent antitumour agent, mitozolomide (CCRG 81010; M & B 39565; NSC 353451). Biochem. Pharmacol. 33 (14): 2185–2192 (1984).PubMedCrossRefGoogle Scholar
  8. 8.
    N.W. Gibson, J.A. Hartley, W.B. Mattes, K.W. Kohn, L.C. Erickson. The effects of pretreatment of human tumor cells with MNNG on the DNA crosslinking and cytotoxicity of two chloroethylating agents. Abstract: International Conference on Mechanisms of DNA Damage and Repair. Implications for Carinogenesis and Risk Assessment. Gaithersburg, Maryland. (June 2–7, 1985).Google Scholar
  9. 9.
    J.A. Hartley, N.W. Gibson, K.W. Kohn, W.B. Mattes. DNA sequence selectivity of guanine-N7 alkylation by three antitumor chloroethylating agents. Cancer. Res. 46 (4, Pt. 2): 1943–1947 (1986).PubMedGoogle Scholar
  10. 10.
    M.J. Tisdale. Antitumour imidazotetrazines — XV. Role of guanine 0 (6) alkylation in the mechanisms of cytotoxicity of imidazotetrazines. Biochem. Pharmacol. 38 (4): 457–462 (1987).CrossRefGoogle Scholar
  11. 11.
    V.L. Bull, M.J. Tisdale. Antitumour imidazotetrazines-XVI. Macromolecular alkylation by 3-substituted imidazotetrazines. Biochem. Pharmacol. 36 (19): 3215–3220 (1987).PubMedCrossRefGoogle Scholar
  12. 12.
    J. Jelinek, K. Kleibl, T.M. Dexter & G.P. Margison. Increased resistance to the toxic effects of mono and bifunctional alkylating agents in murine hemopoietic cells expressing DNA alkyltransferase genes from E. coli. Proc. Ann. Meeting, Amer. Assoc. Cancer Res. 28: 112. Abstract (1987).Google Scholar
  13. 13.
    J.A. Hickman, M.F. Stevens, N.W. Gibson, S.P. Langdon, C. Fitzjames, F. Lavelle, G. Atassi, E. Lunt & R.M. Tilson. Experimental antitumour activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1,d]-1,2, 3,5-tetrazin-4(3H)-one(mitozolomide), a novel broad spectrum agent. Cancer. Res. 45 (7): 3008–3013 (1985).PubMedGoogle Scholar
  14. 14.
    O. Fodstad, S. Aamdal, A. Pihl & M.R. Boyd. Activity of mitozolomide (NSC 353451), a new imidazotetrazine, against xenografts from human melanomas, sarcomas, and lung and colon carcinomas. Cancer Res. 45, 1778–1786 (1985).PubMedGoogle Scholar
  15. 15.
    M.C. Bibby, J.A. Double, I.A. Wahed, N. Hirbawi & T.G. Baker. The logistics of broader pre-clinical evaluation of potential anti-cancer agents with reference to anti-tumour activity and toxicity of mitozolomide. Br. J. Cancer 58 (2): 139–143 (1988).PubMedCrossRefGoogle Scholar
  16. 16.
    C.J. Brindley, P. Antoniw & E.S. Newlands. Plasma and tissue disposition of mitozolomide in mice. Br. J. Cancer 53, 91–97 (1986).PubMedCrossRefGoogle Scholar
  17. 17.
    E.S. Newlands, G. Blackledge, J.A. Slack, C. Goddard, C.J. Brindley, L. Holden & M.F.G. Stevens. Phase I clinical trial of mitozolomide. Cancer Treatment Reports 69, 7–8 (July/Aug. 1985).Google Scholar
  18. 18.
    P. Herait, P. Rougier, J. Oliveira, P.M. Delgado, L.F. May, M. Hayat & J.P. Armand. Phase II study of mitozolomide (M & B 39565) in colorectal and breast cancer. Invest. New Drugs 6 (4): 323–325 (1988).PubMedCrossRefGoogle Scholar
  19. 19.
    G. Blackledge, J.T. Roberts, S. Kaye, R. Taylor, J. Williams, B. De Stavola & B. Uscinska. A phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder. Eur. J. Cancer. Clin. Oncol, 25/2: 391–392 (1989).PubMedCrossRefGoogle Scholar
  20. 20.
    M. Harding, D.Northcott, J. Smyth, N.S.A. Stuart, J.A. Green & E. Newlands. Short communication in: Phase II evaluation of mitozolomide in ovarian cancer. Br. J. Cancer 57: 113—114 (1988).PubMedGoogle Scholar
  21. 21.
    J.P. Neijt, M.E. van der Burg, J.P. Guastalla, M. George, J.B. Vermorken & N. Rotmentsz. Mitozolomide in patients with advanced ovarian carcinoma: A Phase II study of the EORTC Gynecological Cancer Cooperative Group. Abstract: Proc. ECCO-4. Fourth European Conference on Clinical Oncology and Cancer Nursing; Federation of European Cancer Societies, Madrid, p. 214. (Nov. 1–4, 1987).Google Scholar
  22. 22.
    A.T. van Oosterom, G. Stoter, A.V. Bono, T.A.W. Splinter, S.D. Fossa, A.J. Verbaeys, P.H.M. de Mulder, M. de Pauw & R. Sylvester. Mitozolomide in advanced renal cancer: A Phase II study in previously untreated patients from the EORTC Genitourinary Tract Cancer Cooperative Group. Eur. J. Cancer Clin. Oncol. 25, 8: 1249–1250 (1989).PubMedCrossRefGoogle Scholar
  23. 23.
    S. Gundersen, S. Aamdal & O. Fodstad. Mitozolomide (NSC 353451), a new active drug in the treatment of malignant melanoma. Phase II trial in patients with advanced disease. Br. J. Cancer 55: 433–435.Google Scholar
  24. 24.
    J.H. Schornagel, G. Simonetti & J.G. McVie. Phase I study of mitozolomide (NSC 353451) using a daily x 5 schedule. Proc. Fifth NCI-EORTC Symposium on New Drugs in Cancer Therapy. Abstract. (1986).Google Scholar
  25. 25.
    E.S. Newlands, J. Slack, G. Blackledge, N. Stuart, C. Quartermain, R. Hoffman & M.F.G. Stevens. Proc. Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy. Abstract No. 419. (1989).Google Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • E. S. Newlands
    • 1
  • G. R. P. Blackledge
    • 2
  • J. Slack
    • 3
  • N. S. A. Stuart
    • 2
  • M. F. G. Stevens
    • 3
  1. 1.Dept. of Medical OncologyCharing Cross HospitalLondonUK
  2. 2.Dept. of MedicineQueen Elizabth HospitalBirminghamUK
  3. 3.Dept. of Pharmaceutical SciencesAston UniversityBirminghamUK

Personalised recommendations